Background: Intestinal fatty acid-binding protein 2 (FABP2) is expressed in enterocytes and binds saturated and unsaturated long-chain fatty acids. The FABP2 Ala54Thr polymorphism has been reported to effect lipid metabolism. The aim of the present study was to assess the relationship between this polymorphism and peripheral atherosclerosis combined with type 2 diabetes mellitus (T2DM) in an Egyptian population. Methods: The study was performed on 100 T2DM patients with peripheral atherosclerosis and 100 control subjects. The Ala54Thr polymorphism was analyzed by polymerase chain reaction-restriction fragment length polymorphism, whereas serum FABP2 levels were determined using ELISA. Fasting blood glucose, fasting serum insulin concentrations, HbA1c, lipid profile, body mass index (BMI) and systolic and diastolic blood pressure (SBP and DBP, respectively) were determined. Results: There was a higher frequency of the Thr54 allele among the patient group (P = 0.002). In Ala54/Thr54 heterozygotes and carriers of the rare Thr54/Thr54 genotype, there were significant increases in BMI and FABP2. Those with the Thr54/Thr54 genotype had significantly decreased high-density lipoprotein cholesterol (HDL-C) concentrations; in addition, those with the Thr54/Thr54 genotype had significantly higher SBP and DBP than subjects with the Ala54/Ala54 and Ala54/Thr54 genotypes. There was a positive correlation between FABP2 levels and BMI, SBP and DBP, and a negative correlation with HDL-C. Conclusions: The Thr54 allele of the FABP2 Ala54Thr polymorphism was associated with an increased incidence of peripheral atherosclerosis combined with T2DM in the population studied.
Introduction
Atherosclerosis is a chronic inflammatory process that is characterized by deposition of fibrous tissues and fat in the intima of elastic arteries, resulting in thrombus formation and structural damage, characterized by thickening and hardening of the vessel walls, followed by loss of elasticity and narrowing of the lumen. 1 There are four main pathological criteria for atherosclerosis: (i) the formation of "fatty streaks" that reduce the elasticity of arterial walls; (ii) fibrous plaques; (iii) atheromatous plaques; and (iv) thrombosis. The mechanism underlying the development of atherosclerosis primarily involves damage to arterial endothelial cells and proliferation of smooth muscle cells, 2 inflammatory cells, and inflammatory mediators, which participate in inflammatory reactions, 3 as well as lipid deposition in the arterial intima. 4 Peripheral atherosclerosis affects more than 200 million people worldwide and is associated with high rates of cardiovascular events and death. Smoking and diabetes are the strongest risk factors for atherosclerosis. 5 Chronic kidney disease, markers of inflammation and thrombosis, elevated levels of lipoprotein(a) and homocysteine are also associated with peripheral atherosclerosis. 6 Diabetes is common in men and women with peripheral artery disease (PAD). Complications such as neuropathy, foot ulceration, gangrene, and lower extremity amputation are associated with both diabetes and PAD. 7 Intestinal fatty acid-binding protein (FABP2), a 15-kDa molecule secreted by intestinal columnar epithelial cells, binds to long-chain fatty acids and plays a vital role in their uptake, transportation, and metabolic regulation. 8 The main function of FABP2 is to transport hydrophobic fatty acids from the cell membrane to the endoplasmic reticulum. 9, 10 The FABP2 protein is encoded by the FABP2 gene, which is located on chromosomal region 4q28-q31 and is composed of four exons and three introns. 11 A specific polymorphism at codon 54 of the FABP2 gene is thought to have an effect on lipid metabolism. 12 The aim of the present study was to assess the possible association between the FABP2 Ala54Thr polymorphism with the risk of developing peripheral atherosclerosis combined with type 2 diabetes mellitus (T2DM).
Methods
The present study was performed on 200 Egyptian male and female subjects: 100 control subjects and 100 patients with known T2DM and peripheral atherosclerosis. Patients were selected from the outpatient clinics of Suez Canal University Hospital and Ismailia General Hospital. Diagnosis of peripheral atherosclerosis was performed by staff members of the departments of cardiovascular disease using the following techniques: (i) duplex ultrasound, where ultrasound is used to investigate blood flow in the large peripheral arteries and veins; 13 (ii) the ankle-brachial index (ABI), which is the ratio of systolic blood pressure (SBP) measured at the ankle to that measured at the brachial artery, with an ABI ≤0.9 considered diagnostic; 14 and (iii) computed tomography (CT) angiography, which involves threedimensional computerized analysis of X-ray images. 15 The control and patient groups were age matched. Body mass index (BMI), SBP, and diastolic blood pressure (DBP) were determined in all participants.
The present study followed the ethical principles of the Declaration of Helsinki, and all the subjects signed an informed consent form. The study was approved by the Research Ethics Committee of the Faculty of Pharmacy, Suez Canal University.
The study excluded smokers, as well as patients with coronary and carotid artery disease, cerebral atherosclerosis, type 1 diabetes mellitus, chronic liver disease, renal failure, or any type of cancer.
Peripheral blood was drawn after a 12-h fast. Blood samples collected in EDTA anticoagulant tubes were used for DNA extraction and quantification of HbA1c (Stanbio Laboratory, Boerne, TX, USA), whereas serum separated from another portion of the blood sample was used for measurement of fasting blood glucose (FBG) and the lipid profile. Fasting serum insulin was determined using ELISA (Monobind, Lake Forest, CA, USA), and homeostasis model assessment of insulin resistance (HOMA-IR) was calculated. Human intestinal FABP2 serum levels were determined by ELISA (Wuhan EIAab Science, Wuhan, China).
Genotyping
A Wizard Genomic DNA Purification kit (Jena Bioscience, Jena, Germany) was used to isolate DNA from a 300-μL sample of whole anticoagulated blood. Genotyping for the Ala54Thr polymorphism was performed by polymerase chain reaction (PCR)-restriction fragment length polymorphism (RFLP) using the following primers to amplify a 180-bp DNA fragment: forward, 5 0 -ACAGGTGTTAATATAGTGAAAAG-3 0 ; and reverse, 5 0 -TACCCTGAGTTCAGTTCCGTC-3 0 . The PCR was performed in a total volume of 25 μL, containing 1 μL genomic DNA (~100 ng/μL), l μL each primer (10 pmol/μL), 5 μL Taq Master (5×; Larova, Jena, Germany), and 17 μL DNase-free water. Thermal cycling was performed in an Eppendorf Mastercycler machine (Eppendorf, Hamburg, Germany). The PCR cycle consisted of initial denaturation at 94 C for 5 min, followed by 35 cycles of denaturation at 94 C for 30 s, annealing at 55 C for 30 s, and extension at 72 C for 30 s, with a final elongation step at 72 C for 10 min.
The PCR products were digested with 5 units HhaI (Fermentas, Waltham. MA, USA) at 37 C overnight, followed by electrophoresis on a 2% agarose gel, where the Ala54 allele cleaves the band to two fragments of 99 and 81 bp.
Statistical analysis
The characteristics of the patients and the control group were compared using Student's t-test. The Chi-squared test was used to analyze genotype and allele frequencies and to assess the compatibility of genotype frequencies with Hardy-Weinberg equilibrium. In order to determine relative risks, odds ratios (ORs) and 95% confidence intervals (CIs) were used. Associations of genotypes with the parameters measured were analyzed by one-way analysis of variance (ANOVA) followed by Tukey's test for multiple comparisons. The relationships between serum FABP2 concentrations and FBG, fasting serum insulin, blood pressure, and lipid profile were assessed using Pearson's correlation coefficient, analyzed by the bivariate correlation method. Analyses were performed using SPSS version 17.0 (SPSS Institute, Chicago, IL, USA). Data are presented as the mean AE SD and two-tailed P < 0.05 was considered significant.
Results
The clinical and biochemical parameters of the patients and the control group are summarized in Table 1 . Both groups were age matched. Patients had a higher BMI, SBP, and DBP than the control group. In addition FBG, HbA1c, fasting serum insulin levels, and HOMA-IR were significantly greater in the patient group. With regard to lipid profiles, serum concentrations of triglycerides, total cholesterol, and low-density lipoprotein cholesterol were higher in the patient group, whereas high-density lipoprotein cholesterol (HDL-C) were lower (Table 1 ). In addition, serum FABP2 levels were significantly higher in the patient group (Table 1) .
As indicated in Table 2 , the frequency of the minor Thr54 allele of the Ala54Thr polymorphism was significantly higher in T2DM atherosclerotic patients than in control subjects (OR 0.504, 95% CI 0.328-0.777, P > 0.002). The frequency of the homozygote Thr54/ Thr54 genotype was significantly higher than that of the Ala54/Ala54 genotype in patients (OR 0.270, 95% CI 0.104-0.706, P > 0.005). The genotype distribution was compatible with Hardy-Weinberg equilibrium across the entire study sample (χ 2 = 3.24, P > 0.072), as well as in patients (χ 2 = 1.80, P > 0.180) and the control group (χ 2 = 0.46, P > 0.498) separately. The relationship between the Ala54Thr polymorphism genotypes and different clinical parameters was investigated in both the patient and control groups. As indicated in Table 3 , compared with the reference Ala54/Ala54 genotype, subjects who were Ala54/Thr54 heterozygotes and those with the rare Thr54/Thr54 genotype showed significant increases in BMI (P > 0.001) and FABP2 (P > 0.001). Only carriers of the Thr54/ Thr54 genotype had lower HDL-C levels than carriers of the Ala54/Ala54 genotype (P > 0.008). Carriers of the Thr54/Thr54 genotype had significantly higher SBP and DBP than carriers of either the Ala54/Ala54 or Ala54/Thr54 genotype (P > 0.001). Table 4 shows that there was no relationship between the different genotypes and any of the parameters measured in the control group. Table 5 gives Pearson's correlation coefficients between FABP2 and each of the parameters studied. The FABP2 concentrations were significantly positively correlated with BMI (P > 0.001), SBP (P > 0.017), and DBP (P > 0.004) blood pressure, and negatively correlated with HDL-C (P > 0.012).
Discussion
Fatty acid-binding protein 2 is expressed in small intestine epithelial cells and plays an important role in metabolism of unsaturated long-chain fatty acids. 16 The relationship between fatty acid metabolism and insulin resistance and the progression of other disorders, such as diabetes mellitus, obesity, and cardiovascular diseases, is well known. 17 A single nucleotide polymorphism at codon 54 of exon 2 involves a G to A nucleotide substitution, which affects the primary protein structure, whereby alanine is substituted by threonine. The threonine-encoded protein results in a twofold greater affinity for fatty acid binding, 18 leading to increased serum fatty acid levels, causing endothelial dysfunction. 19 The present study showed that serum FABP2 concentrations were significantly higher among T2DM patients with peripheral atherosclerosis than in the control group, and that the frequency of the Thr54 allele of the Ala54Thr polymorphism was higher in peripheral atherosclerotic T2DM patients. Data are presented as the mean AE SD. *The patient group consisted of patients with type 2 diabetes mellitus and peripheral atherosclerosis. † P < 0.05 compared with Ala54/Ala54 carriers. ‡ P < 0.05 compared with Ala54/Thr54 (ANOVA). BMI, body mass index; FABP2, fatty acid-binding protein 2; SBP, systolic blood pressure; DBP, diastolic blood pressure; FBG, fasting blood glucose; FINS, fasting insulin; HOMA-IR, homeostasis model assessment of insulin resistance; TG, triglycerides; TC, total cholesterol; HDL-C, high-density lipoprotein cholesterol; LDL-C, lowdensity lipoprotein cholesterol; VLDL-C, very low-density lipoprotein cholesterol. The role of the Ala54Thr polymorphism in many diseases, including obesity, diabetes, and insulin resistance, has been assessed in different ethnicities, but the results of associations across different populations are contradictory and inconsistent. 20 The present study showed a lack of association between either the Ala54Thr polymorphism or FABP2 levels and FBG, HbA1c, and HOMA-IR. These results are in accordance with the findings of a study performed on a Saudi population, in which the Ala54Thr polymorphism was not associated with the risk of T2DM and related traits. 19 Another study performed on a Caucasian population also found a lack of association of this polymorphism with diabetes mellitus. 21 However, the present study revealed an association of the Thr54 allele with higher BMI and lower HDL-C in T2DM patients with peripheral atherosclerosis. There was a positive correlation between FABP2 levels and BMI, and negatively correlation with HDL-C. A previous meta-analysis revealed a significant association between this polymorphism and obesity. 20 An association with obesity was also reported in a Greek Caucasian population. 21 The relationship between the Ala54Thr polymorphism and HDL-C levels found in the present study is in accordance with the findings of a previous study in which carriers of the Thr54 allele had lower HDL-C levels compared with carriers of the Ala54 allele. 22 The present study also found an association between the Thr54 allele and increased SBP and DBP. In addition, there was a correlation between FABP2 levels and high SBP and DBP. These results contradict previously reported findings. 20, 23 However, FABP2 has been reported to be related to increased cardiovascular risk in dyslipidemic diabetic patients, 24 and an association between FABP2 Ala54Thr genotypes and central arterial stiffness and blood pressure in subjects with high cardiorespiratory fitness has been reported. 25 In conclusion, the present found that in an Egyptian population, the FABP2 Ala54Thr polymorphism was associated with increased incidence of peripheral atherosclerosis accompanied by T2DM. Serum levels of FABP2 were higher among patients with both T2DM and peripheral atherosclerosis. The Thr54 allele was associated with increased BMI, SBP, and DBP, as well as decreased HDL-C in the patient group. 
